Impact of carboplatin desensitization therapy on progression-free survival in gynecologic cancers

Desensitized patients demonstrated increased progression-free survival as compared to cisplatin patients. This progression-free survival advantage may be due to the increased toxicity profiles noted for cisplatin and comparatively better tolerability of carboplatin desensitization. Progression-free survival was similar between carboplatin-desensitized and alternative therapy patients, as well as platinum-based and alternative therapy patients.